Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

Conditions: Vaccine-Preventable Diseases; Herpes Zoster Interventions: Biological: CVI-VZV-001; Biological: Shingrix Sponsors: CHA Vaccine Institute Co., Ltd. Recruiting

https://clinicaltrials.gov/study/NCT06137755

Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials

More News: Herpes | Research | Shingles (Herpes Zoster) Vaccine | Vaccines | Varicella-Zoster Virus Vaccine